The latest price target for Indaptus Therapeutics (NASDAQ:INDP) was reported by HC Wainwright & Co. on June 17, 2024. The analyst firm set a price target for $12.00 expecting INDP to rise to within 12 months (a possible 627.27% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Indaptus Therapeutics (NASDAQ:INDP) was provided by HC Wainwright & Co., and Indaptus Therapeutics reiterated their buy rating.

The last upgrade for Indaptus Therapeutics Inc happened on October 19, 2021 when Maxim Group raised their price target to $16. Maxim Group previously had a hold for Indaptus Therapeutics Inc.

There is no last downgrade for Indaptus Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Indaptus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Indaptus Therapeutics was filed on June 17, 2024 so you should expect the next rating to be made available sometime around June 17, 2025.

While ratings are subjective and will change, the latest Indaptus Therapeutics (INDP) rating was a reiterated with a price target of $12.00 to $12.00. The current price Indaptus Therapeutics (INDP) is trading at is $1.65, which is out of the analyst’s predicted range.